




The 7 truths of impurities and their reference standards –
FDA's and other regulators' viewpoints and further stories (Part 1)



Dr. Christian Zeine
LGC Standards GmbH

Webinar Series 2013
July 2013

Quick guide to the webinar tools



Content



ICH guidelines Q3A and Q3B on impurities are to be applied to generic drugs as well



An incompletely characterised impurity reference standard might be cheap, but could result in a large amount of hidden costs



It is not correct to assume an assay of 100% for a USP reference standard when there is no assay information on the label



Pharmacopoeial monographs might change, and so might the supply of impurity reference standards



Regulators accept our impurity reference standards




Impurity descriptions from pharmacopoeias will not necessarily match each other



Our impurity reference standards can be used universally, and might be less expensive than you think

Our  truths of impurities and their reference standards

Truth #1 – ICH Q3A and Q3B to be applied to generics



Truth #1 – ICH Q3A and Q3B to be applied to generics



- ICH: International Conference on Harmonisation
 - Members from regulation authorities and industrial pharmaceutical associations
 - From Japan, USA and Europe
- Three ICH Guidelines important (www.ich.org)
 - Q3A(R2): Impurities in new drug substances
 - Q3B(R2): Impurities in new drug products
 - Q3C(R5): Impurities – Guideline for residual solvents
 - A fourth one (Q3D) on heavy metal impurities to come

Truth #1 – ICH Q3A and Q3B to be applied to generics



- Europe
 - European Pharmacopoeia (Ph.Eur.)
 - Two documents of importance:
General monograph Substances for pharmaceutical use (2034)
General chapter Control of impurities in substances for pharmaceutical use (5.10.)
 - Above documents link applicable
Ph.Eur. monographs (new monographs) to ICH Q3A and its thresholds

Maximum Daily Dose ¹	Reporting Threshold ^{2,3}	Identification Threshold ³	Qualification Threshold ³
≤ 2g/day	0.05%	0.10% or 1.0 mg per day intake (whichever is lower)	0.15% or 1.0 mg per day intake (whichever is lower)
> 2g/day	0.03%	0.05%	0.05%

Truth #1 – ICH Q3A and Q3B to be applied to generics



- Europe
 - European Medical Agency (EMA):
Guideline on *Control of Impurities in Pharmacopoeial Substances* (CPMP/QWP/1529/04) from 2004
 - Guideline requests that marketing approval for medicinal products should only be granted when referred-to monographs for pharmacopoeial ingredients are compliant with **2034** and **5.10**.
 - Also the guideline requests that EDQM should not grant CEPs (certificates of suitability) based on old monographs not compliant with **2034** and **5.10**.

Truth #1 – ICH Q3A and Q3B to be applied to generics



- USA
 - FDA issued two guidances for industry ANDAs: Impurities in drug substances / products
 - June 2009 (drug substances), November 2010 (drug products)
 - Statement there
 - ICH Q3A and Q3B were developed for new drug applications (NDAs)
 - However, FDA takes position that ICH principles are applicable to ANDAs (abbreviated NDAs, i.e. generic products) as well:

“FDA believes that much of the content of the Q3A(R) guidance applies to ANDAs. See especially sections I through V and the Attachment, Thresholds.”


New FDA impurity guidance: Relevant points

- Setting acceptance criteria
 - First point of reference:
Pharmacopoeias (namely USP)
 - If impurity specified in USP, then specification there should be kept
 - Probably other pharmacopoeia specifications would be acknowledged as well
 - If pharmacopoeia specification cannot be kept then impurity enters into qualification process
 - If impurity is not specified in compendia
 - Use decision tree provided (based on ICH design)

New FDA impurity guidance: Decision tree



Check impurity level with a dedicated reference standards before taking further actions!



Truth #3 – Pharmacopoeial reference standards: Incorrect assumption of assay of 100% when nothing is written on label



Truth #3 – Pharmacopoeial reference standards



- Most common pitfalls
 - Not for universal use, only in combination with the compendial books
 - EP CRS and USP RS only designed for (often) just a single purpose
 - Not suitable necessarily for non-pharmacopoeial purposes
 - User is responsible for off-compendial use

Truth #3 – Pharmacopoeial reference standards



- Most common pitfalls
 - Not for universal use, only in combination with the compendial books
 - **USP General Chapter <11>** : "They (*USP Reference Standards*) are explicitly required in many Pharmacopoeial assays and tests and are provided solely for such use. Assessment of the suitability for use in other application(s) rests with the purchaser."
 - **General text 5.12., Ph. Eur.:**
„EPCRS. A substance (*EP CRS*) ... intended for use as stated in a monograph ... of the Ph. Eur.
...
Reference standards are ... suitable for their intended purpose; they are not necessarily suitable for other purposes. ...
For any purposes other than that for which it has been established, its suitability ... has to be fully demonstrated."

Truth #3 – Pharmacopoeial reference standards



- Most common pitfalls
 - The “assay rumour”:
“When there’s nothing written on the label, the assay can be taken as 100%.”
 - Not true, misunderstood USP passage (General Notices 5.80.): "Unless a reference standard label bears a specific potency or content, assume the reference standard is 100.0% pure in the *official* application."
 - 100% pure for official use of identification tests does not mean 100% pure for assay purposes outside pharmacopoeia
 - Ph.Eur. not having such a statement, but similar approach in place for some of their quantitatively used impurity reference standards

Truth #3 – Pharmacopoeial reference standards



- Most common pitfalls as regards impurities
 - Pharmacopoeial impurity standards are often designed only for qualitative use
 - Assay then not known, can be far away from 100%
 - Calculation with 100% for non-pharmacopoeial purposes then can result in serious over-estimation of impurities
 - Causing OOS results, unnecessary qualification studies etc.
 - Better use a dedicated impurity reference standard
 - Apart from pharmacopoeia materials
 - Well characterised, with detailed certificate of analysis
 - We supply approx. 3000 of such impurity reference standards

CofA: Impurity RS



Excellence through measurement

CERTIFICATE
Reference Substance
4-Methoxy-2-(2,2-dimethylpropanoic acid)benzimidazole
2-(2-methylpropanoic acid)ethyl 2-(2-methylpropanoic acid)ethyl
1-Clear (Diminorone Sulphate B-Complex)

I. Identity
The identity of the reference substance was established by following procedure:
Dx. ¹³C-NMR Spectrum
Concentration: 400.00% (w/w) in CDCl₃.
The substance is confirmed with the signals of the spectrum and their assignment:


II. IR Spectrum
Method: International Trade Reference Product - Transmission based on IR of 100% Solution
The signals of the IR spectrum and their assignment are compared with the reference substance:

III. Purity
The purity of the reference substance was assessed by high performance liquid chromatography (HPLC):
HPLC Conditions:
Injection: 10 µL
Injection Volume: 10 µL
Injection Concentration: 1.0 mg/mL
Injection Temperature: 20 °C
Injection Pressure: 1.0 MPa
Injection Time: 1.0 min
Injection Volume: 10 µL
Injection Concentration: 1.0 mg/mL
Injection Temperature: 20 °C
Injection Pressure: 1.0 MPa
Injection Time: 1.0 min

IV. Mass Spectrum
Method: A.2.04.02.01 - Acquisition Temperature: 200 °C, Acq. File:
The signals of the mass spectrum and their assignment are compared with the reference substance:

V. Final Result
The purity of the reference substance is 100.00% (w/w).
The assay for it is expressed in the assay based on the mass fraction and is not an additional independent measurement.
Assay Date: 2012-08-08
LGC Group
Dr. Stefan Günther
Product Manager


CofA: Impurity RS



CERTIFICATE

Reference Substance

4-Methoxy-2-[[[(5-methoxy-1H-benzimidazol-2-yl)sulphonyl]methyl]-3,5-dimethylpyridine 1-Oxide (Omeprazole Sulphone N-Oxide)



Molecular Formula: $C_{17}H_{19}N_3O_6S$
Molecular Weight: 377.42
CAS Number: [158812-85-2]

Catalogue Number: MM0095.16
Lot Number: 15573
Long-term Storage: 2 to 8 °C, dark
Appearance: white solid
Melting Point: 185 °C (dec.)
Assay 'as is': 99.2 %

Date of shipment:


This certificate is valid for two years from the date of shipment provided the substance is stored under the recommended conditions.



CofA: Impurity RS



Excellence through measurement



I. Identity

The identity of the reference substance was established by following analyses.

Ia. ¹H-NMR Spectrum



Conditions: 400 MHz, DMSO-d₆

The structure is confirmed with the signals of the spectrum and their interpretation.


CofA: Impurity RS





Excellence through measurement



The signals of the mass spectrum and their interpretation are consistent with the structural formula.



Cof



Area Percent Report - Sorted by Signal

Pk #	Retention Time	Area	Area %
1	3.66	1422	0.02
2	5.95	2481	0.04
3	8.40	6745401	99.85
4	12.72	1480	0.02
5	15.18	3383	0.05
6	23.07	1693	0.03
Totals		6755860	100.00

For the calculation the system peaks were ignored. The content of the analyte was determined as ratio of the peak area of the analyte and the cumulative areas of the purities, added up to 100 %.

Results:

Average 99.85 %
Number of results n=3
Standard deviation 0.01 %

III. Water Content

Method: Karl Fischer titration

Results:

Average	0.20 %
Number of results	n=3
Standard deviation	0.01 %

IV. Residual Solvents

Method: ¹H-NMR


Result: 0.46 % Chloroform
0.04 % *n*-Hexane

V. Final Result

Total impurities (HPLC)	0.15 %
Water content	0.20 %
Residual solvents	0.50 %
Assay (100 % method) ¹	99.15 %

The assay is assessed to be 99.2 % 'as is'

The assay 'as is' is equivalent to the assay based on the not anhydrous and not dried substance respectively.




Retention Time	Area	Height	Width
2.00	1000	100	0.50
3.00	2000	200	0.50
4.00	3000	300	0.50
5.00	4000	400	0.50
6.00	5000	500	0.50
7.00	6000	600	0.50
8.00	7000	700	0.50
9.00	8000	800	0.50
10.50	100000	10000	1.00
11.00	9000	900	0.50
12.00	8000	800	0.50
13.00	7000	700	0.50
14.00	6000	600	0.50
15.00	5000	500	0.50
16.00	4000	400	0.50
17.00	3000	300	0.50
18.00	2000	200	0.50
19.00	1000	100	0.50
20.00	1000	100	0.50
21.00	1000	100	0.50
22.00	1000	100	0.50
23.00	1000	100	0.50
24.00	1000	100	0.50
25.00	1000	100	0.50
26.00	1000	100	0.50
27.00	1000	100	0.50
28.00	1000	100	0.50
29.00	1000	100	0.50
30.00	1000	100	0.50

¹ The calculation of the 100 % method follows the formula:

$$\text{Assay (\%)} = (100 \% - \text{KF} - \text{RES}) * \frac{\text{Purity HPLC (\%)}}{100 \%}$$

Water (KF) and Residual solvents (RES) are considered as absolute contributions, HPLC purity is considered as relative contribution.

Truth #5 – Regulators accept our impurity standards




Truth #5 – Regulators accept our impurity standards



- For impurity standards, we provide the most detailed certificates available
- Frequently used in dossiers
- Readily accepted by regulatory agencies worldwide
 - FDA in the States
 - EMA in Europe (and national agencies)
 - MHLW in Japan
 - RoW

Truth #7 – Our impurity standards can be used universally, and might be less expensive than you think



Truth #7 – Imps. standards useful universally, less expensive than often thought



- Our impurity reference standards
 - Unit size in most cases 100 mg, substances more rare or difficult to synthesise: unit size 50 mg
 - Most customers do not want smaller unit sizes
 - With detailed certificate
 - Identity: NMR (for new batches - since Sept 2011 - also MS and IR data)
 - Organic purity, water, residual solvents
 - Assay calculation
- Can be used in almost any analytical application

Truth #7 – Imps. standards useful universally, less expensive than often thought



- When comparing to other commercial providers
 - On a price per mg basis
 - Other commercial providers often more expensive for their materials, always advisable to check price and documentation beforehand
 - CofA of other providers
 - In most cases deficiencies compared to our CofA
 - No supplier provides more detailed CofA for impurity reference standards

Truth #7 – Imps. standards useful universally, less expensive than often thought

- When comparing to materials from pharmacopoeia commissions
 - Comparison to USP, on a price per mg basis:
 - For most cases, LGC Standards less expensive
 - Furthermore detailed CofA is provided for LGCS impurities
 - USP materials with restricted use
 - Comparison to Ph.Eur, on a price per mg basis:
 - In most cases, Ph.Eur. cheaper
 - But no certificate provided with Ph.Eur. materials
 - Very restricted use for Ph.Eur. materials

Closing remarks

- LGC Standard is part of LGC group
- S&T section of LGC acts as NMI for chemical and biochemical measurement in the UK (comparable to NIST in the US)



Closing remarks

- Manufacturing of pharmaceutical reference materials
 - For APIs and impurities, over 3,000 standards
 - Metal impurity materials (suitable for ICP-OES and ICP-MS applications)
 - Constantly new developments
 - **Launch of primary standard catalogue products in October 2013!**
 - ISO 34 and ISO 17025 accredited
- Contract services
 - Custom synthesis (for RSs)
 - Custom analysis
 - Characterisation of customer material
 - Customised packaging and storage



Service modules

Process steps based on internal quality standards; ISO 17025 or ISO Guide 34

1
Sourcing

2
Quality
Control

3
RAW-
material

4
Packaging

5
Characte-
risation

6
Certifi-
cation

7
Storage

8
Distribution

Supplementary processes for stability monitoring and re-testing

Closing remarks



- Further webinars in July/August, registration possible under <http://pharma.lgcstandards.com/>
 - On website, look under ‘Events’
Always on a Thursday, always 10.30 – 11.15
 - 1st of August 2013:
Seven truths of impurities and their reference standards, Part 2

QUESTIONS?



Now, or to christian.zeine@lgcstandards.com

